Assistant Professor of Gastroenterology @unito Consultant Hepatologist @cittasalute_to
Torino, Piemonte
Joined July 2017
- Tweets119
- Following215
- Followers186
- Likes267
Pinned Tweet
Thanks @my_ueg for this great opportunity! Looking forward to developing my very first project with a strong research team 🔥 🔝 learning and nwetworking @schattenbergJ @UnimedizinMainz @unito #UEG #livertweet #nafld – at Moncalieri, Piemonte
Congratulations to Dr @angeloarmandi, #UEGResearch Fellow 2023! 🎉 Angelo will be joining the team @schattenbergj at the University Medical Center of Mainz for his project "Immune activation and the liver-spleen axis in Non-Alcoholic Steatohepatitis". All the best, Angelo!
Angelo Armandi, MD, PhD retweeted
Proud to share our recent publication @JHepatology
This is the first international multicenter study evaluating the clinical and prognostic impact of the first and further decompensation in patients with #MASLD.
Grateful to all collaborators!
Angelo Armandi, MD, PhD retweeted
Read the #GUTOnline paper by Lai et al on
"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease" via
bit.ly/3FObRzm
#MASLD #HCC @hanneshagstrom @wonglaihung @gra_penni @AngeloArmandi @YingShang1 @mromerogomez @TerryYip12
Angelo Armandi, MD, PhD retweeted
🚀Launching the #LiverRiskScore app!
📱A simple digital tool to spot liver disease risk early using routine clinical data! Easy to use, built for everyday care.
🔗iOS: apps.apple.com/us/app/liverr…
🔗Android play.google.com/store/apps/d…
@IHIEurope @EASLnews
Angelo Armandi, MD, PhD retweeted
#LIVERAIM networking session is starting at track hub8!
Join us and learn from @schattenbergJ and @PoseElisa how #biomarkers of #liverfibrosis can reshapethe future of Hepatology
#livertwitter #EASLCongress
@IHIEurope @EASLedu @EASLnews @AleksanderKrag @JVLazarus @MajaThiele
Angelo Armandi, MD, PhD retweeted
❓Did you miss the second #LIVERAIM webinar?
Check out our Youtube channel and discover what an #earlydiagnosis of #chronicliverdisease truly means for patients!
🎥youtube.com/watch?v=jmw5jpG2…
#LiverTwitter
Angelo Armandi, MD, PhD retweeted
🚀#LIVERAIM is on the move!
Biomarker analysis for early liver fibrosis detection has started at #CORELAB of @hospitalclinic on 22k+ serum samples from general and high-risk populations.
🔎Watch how science is shaping the future!
#livertwitter
@IHIEurope @idibaps @EASLnews
Angelo Armandi, MD, PhD retweeted
What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: authors.elsevier.com/sd/arti…. Congrats to @TerryYip12 and the VCTE-Prognosis Study Team! 🎉 #MASLD #ClinicalResearch
Angelo Armandi, MD, PhD retweeted
Fibrosing MASH (F2-F3) and MASH-cirrhosis/ACLD are clinically relevant entities requiring both liver-targeted and systemic/metabolic management.
In the diabetic population, GLP1-RAs should be preferred for their beneficial impact on liver histology, and safety in Child A cirrhosis. Alternatively, SGLT2i could be used for the positive impact on liver steatosis and CVD prevention.
Resmetirom, where approved, is the treatment of choice for MASH F2-F3 patients. Semaglutide has met both histological endpoints in phase 3 RCT.
A careful management of MASLD-cirrhotic patients is warranted, for the increased risk of liver-related outcomes. Early liver-specific pharmacological treatment is currently being investigated. @AngeloArmandi #SLDSummit
Our latest review on the impact of #PNPLA3 variants on clinical outcomes in #MASLD is out in @LiverInt open access @salvatore_petta @lucavalenti75 @stefano_romeo76
onlinelibrary.wiley.com/doi/… – at Turin, Piedmont
Angelo Armandi, MD, PhD retweeted
Are you a young researcher looking to grow your skills? The #UEGResearch Fellowship offers 12 months at a top European institution to work on a basic or clinical project. 🌍🔬
📅 Apply by Dec 4, 2024! Need a host institution? We’ve got you covered ➡️ bit.ly/3oDfZDO
ALT a man in a white coat
Angelo Armandi, MD, PhD retweeted
What’s up in #MASH #treatment⁉️ #ElisabettaBugianesi and @AlkhouriNaim presenting 🗣️#novel 💊➕💉 and response
Myself added 👨💻📈 #NIT to treatment from #resmetirom and #semaglutide
@my_ueg @DrLoomba @Mayo_liverdoc @ebtapper @NoureddinMD @phil_newsome7 @QAnstee 🪑@HannesHagstrom
Thanks @AlkhouriNaim for sharing! Indeed a hot topic, requiring multiple refinements (biomarkers, natural history, trial eligibility and drug targets) - we have just approached a complex but fascinating field! – at Vienna, Austria
@AngeloArmandi presenting on the 🔥 topic of MetALD! This condition affects 2-4% of the adult population in the US. Worse prognosis than MASLD, increasing cause for liver transplant! How to design MetALD trials?? @juanpabloarab @ebtapper @NoureddinMD @novonordisk
Angelo Armandi, MD, PhD retweeted
Non-Invasive CSPH Estimated Risk (NICER) model including @Echosens SSM by VCTE at 100Hz
👉Developed (2020-2022) & validated (2023) in contemporary pts.
👉Outperforms ANTICIPATE(-NASH): AUC consistently >0.9.
👉Well-calibrated.
👉Sets a new standard IMHO.
#LiverTwitter
🔗👇
Angelo Armandi, MD, PhD retweeted
Applications for the #UEGResearch Fellowship 2025 are open! 🙌
UEG will award 2 fellowships to young researchers to conduct a project with a renowned European PI. 📢 We particularly encourage researchers from Inclusiveness Target Countries to apply ➡ bit.ly/3oDfZDO
ALT an orange background with white text
Angelo Armandi, MD, PhD retweeted
🎉Our new Impact Factor is 9.5🎉
👏Many thanks to the Editorial Team, our peer reviewers, and very innovative authors❗️
@Zucmanrossi
@EASLnews
@EASLedu
#LiverTwitter
Angelo Armandi, MD, PhD retweeted
Latest #GUTVideo by @AngeloArmandi et al on
"Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3VcOPGY
Paper: bit.ly/49y90Dd
#LiverTwitter #MASLD
Angelo Armandi, MD, PhD retweeted
Latest #GUTVideo by @AngeloArmandi et al on
"Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3VcOPGY
Paper: bit.ly/49y90Dd
#LiverTwitter #MASLD
